Related Experiment Video
Updated: Sep 11, 2025

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
Published on: October 20, 2023
Sleep-wake Disorders: Systematic Review of Approved Psychiatric Medications (2008 to 2024) and Pipeline Phase-3
Lauren Dugan1, Aasim Naqvi2, Ashley Ngor3
1California University of Science and Medicine, School of Medicine, Colton.
Purpose:
This systematic review examines the psychiatric medications approved by the Food and Drug Administration (FDA) for sleep-wake disorders within the past 17 years, from 2008 through 2024, to describe the mechanism of action, indications, evidence for efficacy, dosing, and adverse effects for each medication, as well as the medications that are in the pipeline for approval in phase 3.
Methods:
Studies published from January 1, 2008, until December 31, 2024, were identified from the PubMed database using the keywords "sleep*" AND "disorder*" OR "psychopharm*" AND "medic*" OR "pharm*." An independent, focused analysis was conducted, and a consensus was reached on the studies to be included in this systematic review. Key findings were derived from the full text and tables of the selected studies.
Results:
From January 1, 2008, to December 31, 2024, the FDA approved 14 medications for sleep-wake disorders and three pipeline medications as of December 31, 2024, currently in phase 3 clinical trials.
Conclusions:
Through this comprehensive systematic review, stakeholders-including clinicians, researchers, policymakers, and patients-can gain insights into the current treatment landscape and anticipate future therapeutic innovations. This review serves as a resource for guiding treatment decisions and optimizing care for patients with sleep-wake disorders.
Related Concept Videos
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Management of Insomnia
Narcolepsy
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sleepwalking and Sleep Talking
Factors that increase the likelihood of sleepwalking include sleep deprivation and alcohol consumption. Contrary to common beliefs, it is safe...

